What's Happening?
Marengo Therapeutics, a clinical-stage biotechnology company, has reported encouraging interim results from its Phase 2a clinical trial of invikafusp alfa combined with TRODELVY® for treating metastatic breast cancer. The announcement was made at the
2026 American Association for Cancer Research (AACR) Annual Meeting. The trial, known as STARt-002, is a collaboration with Gilead Sciences and focuses on patients with heavily pretreated metastatic triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer. The results showed confirmed complete responses in patients who had not responded to previous therapies. Additionally, Marengo unveiled its second precision T cell activator, IPN01203/STAR0501, developed in partnership with Ipsen, which is advancing into clinical trials. The company highlighted the safety profile of the treatment, which aligns with the known profiles of the individual agents, and the ongoing enrollment of patients across North America.
Why It's Important?
The development of invikafusp alfa in combination with TRODELVY® represents a significant advancement in the treatment of metastatic breast cancer, particularly for patients who have exhausted other options. The confirmed complete responses in heavily pretreated patients underscore the potential of this novel therapy to address a critical unmet need in oncology. The collaboration with Gilead Sciences and Ipsen further strengthens Marengo's position in the biotech industry, showcasing the potential of its STAR platform to develop innovative immunotherapies. The progress of IPN01203/STAR0501 into clinical trials highlights the ongoing efforts to expand treatment options for solid tumors, potentially transforming treatment paradigms and offering new hope to patients.
What's Next?
Marengo plans to continue enrolling patients in the STARt-002 trial, with completion expected later this year. The company aims to present additional data to validate its platform and potentially offer a new treatment option for metastatic breast cancer. The advancement of IPN01203/STAR0501 into clinical trials will be closely monitored, with further updates anticipated as the trials progress. The collaboration with Ipsen is expected to yield more insights into the efficacy and safety of this novel T cell activation approach, potentially leading to new therapeutic strategies for solid tumors.
